Tazemetostat Hydrobromide Tablet — FDA Drug Shortage

To Be Discontinued — Epizyme, Inc. (An Ipsen Company)

The FDA lists a drug shortage record for Tazemetostat Hydrobromide Tablet (tablet) from Epizyme, Inc. (An Ipsen Company) with status To Be Discontinued. The shortage was first posted on 03/27/2026.

Shortage Details

Status
To Be Discontinued
Company
Epizyme, Inc. (An Ipsen Company)
Package NDC
72607-100-00
Dosage Form
Tablet
Presentation
Tazverik, Tablet, 200 mg (NDC 72607-100-00)
Initial Posting
03/27/2026
Revised Date